EA201070281A1 - INDOL-2-ONE DERIVATIVES, DOUBLE SUBSTITUTES IN POSITION 3, THEIR RECEIVING AND THEIR USE IN THERAPY - Google Patents

INDOL-2-ONE DERIVATIVES, DOUBLE SUBSTITUTES IN POSITION 3, THEIR RECEIVING AND THEIR USE IN THERAPY

Info

Publication number
EA201070281A1
EA201070281A1 EA201070281A EA201070281A EA201070281A1 EA 201070281 A1 EA201070281 A1 EA 201070281A1 EA 201070281 A EA201070281 A EA 201070281A EA 201070281 A EA201070281 A EA 201070281A EA 201070281 A1 EA201070281 A1 EA 201070281A1
Authority
EA
Eurasian Patent Office
Prior art keywords
therapy
derivatives
indol
substitutes
double
Prior art date
Application number
EA201070281A
Other languages
Russian (ru)
Other versions
EA019486B1 (en
Inventor
Марко Барони
Летиция Пулео
Original Assignee
Санофи-Авентис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи-Авентис filed Critical Санофи-Авентис
Publication of EA201070281A1 publication Critical patent/EA201070281A1/en
Publication of EA019486B1 publication Critical patent/EA019486B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

Объектом настоящего изобретения являются производные пиндол-2-она, двузамещенные в положении 3, общей формулы (I), в которой Rl, R2, R3, R4, R5, Ar и n такие, как определено по п.1, способ получения и применение указанных соединений в терапии.The object of the present invention are derivatives of pindol-2-one, disubstituted in position 3, of the general formula (I), in which Rl, R2, R3, R4, R5, Ar and n are as defined in claim 1, the method of preparation and use these compounds in therapy.

EA201070281A 2007-08-16 2008-08-14 Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof EA019486B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0705858A FR2920023B1 (en) 2007-08-16 2007-08-16 3-DISUBSTITUTED INDOL-2-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
PCT/FR2008/001190 WO2009056707A2 (en) 2007-08-16 2008-08-14 Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof

Publications (2)

Publication Number Publication Date
EA201070281A1 true EA201070281A1 (en) 2010-08-30
EA019486B1 EA019486B1 (en) 2014-04-30

Family

ID=39197313

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070281A EA019486B1 (en) 2007-08-16 2008-08-14 Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof

Country Status (42)

Country Link
US (2) US20100210662A1 (en)
EP (1) EP2188253B8 (en)
JP (1) JP5685440B2 (en)
KR (1) KR20100051812A (en)
CN (1) CN103443076B (en)
AR (1) AR067937A1 (en)
AT (1) ATE548349T1 (en)
AU (1) AU2008320718B2 (en)
BR (1) BRPI0815171A2 (en)
CA (1) CA2696237C (en)
CO (1) CO6251363A2 (en)
CR (1) CR11273A (en)
CY (1) CY1112809T1 (en)
DK (1) DK2188253T3 (en)
DO (1) DOP2010000050A (en)
EA (1) EA019486B1 (en)
EC (1) ECSP109961A (en)
ES (1) ES2384080T3 (en)
FR (1) FR2920023B1 (en)
GT (1) GT201000032A (en)
HN (1) HN2010000330A (en)
HR (1) HRP20120466T1 (en)
IL (1) IL203956A (en)
JO (1) JO2749B1 (en)
MA (1) MA31742B1 (en)
ME (1) ME00979B (en)
MX (1) MX2010001851A (en)
MY (1) MY149649A (en)
NI (1) NI201000023A (en)
NZ (1) NZ583317A (en)
PA (1) PA8793101A1 (en)
PE (1) PE20090988A1 (en)
PL (1) PL2188253T3 (en)
PT (1) PT2188253E (en)
RS (1) RS52321B (en)
SI (1) SI2188253T1 (en)
TN (1) TN2010000025A1 (en)
TW (1) TWI432423B (en)
UA (1) UA101162C2 (en)
UY (1) UY31297A1 (en)
WO (1) WO2009056707A2 (en)
ZA (1) ZA201001085B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008002427A1 (en) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Pharmaceutical composition comprising 1-chloro-4- (bd-glucopyranos-1-yl) -2- [4 - ((s) -tetrahydrofuran-3-yloxy) benzyl] -benzene combined with 1 - [(4-methylquinazolin- 2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -aminopiperidin-1-yl) xanthine; and its use to treat type 2 diabetes mellitus.
FR2941947B1 (en) * 2009-02-12 2011-03-25 Sanofi Aventis 3-BENZOFURANYL-INDOL-2-ONE 3-DERIVED DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2941946B1 (en) * 2009-02-12 2011-03-25 Sanofi Aventis SUBSTITUTED 3-BENZOFURANYL-INDOL-2-ONE-3-ACETAMIDOPIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
UY32441A (en) 2009-02-13 2010-09-30 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION, TREATMENT METHODS AND ITS USES
AR085689A1 (en) 2011-03-07 2013-10-23 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS OF METFORMIN, LINAGLIPTINE AND AN SGLT-2 INHIBITOR
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
CN108658836B (en) * 2018-05-15 2021-04-20 宁波大学 Preparation method of 3-substituted-3-azidoindole-2-ketone compound
EP3912625A1 (en) * 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2714378B1 (en) * 1993-12-24 1996-03-15 Sanofi Sa Indol-2-one derivatives substituted in 3 with a nitrogen group, their preparation, pharmaceutical compositions containing them.
DE69923692T2 (en) * 1998-08-20 2006-03-23 Sumitomo Pharmaceuticals Co., Ltd. GROWTH HORMONE RELEASING OXINDOL DERIVATIVES
FR2827604B1 (en) * 2001-07-17 2003-09-19 Sanofi Synthelabo NOVEL 1-PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOL-2- ONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JPWO2005035498A1 (en) * 2003-10-08 2006-12-21 住友製薬株式会社 Use of nitrogen-containing bicyclic compounds as food intake regulators

Also Published As

Publication number Publication date
BRPI0815171A2 (en) 2015-03-31
US8202871B2 (en) 2012-06-19
IL203956A (en) 2014-06-30
MA31742B1 (en) 2010-10-01
JO2749B1 (en) 2014-03-15
AU2008320718A1 (en) 2009-05-07
US20110118280A1 (en) 2011-05-19
TWI432423B (en) 2014-04-01
TW200914438A (en) 2009-04-01
CN103443076B (en) 2016-06-22
AU2008320718B2 (en) 2013-09-19
WO2009056707A8 (en) 2010-03-18
FR2920023B1 (en) 2013-02-08
US20100210662A1 (en) 2010-08-19
PE20090988A1 (en) 2009-08-14
CA2696237A1 (en) 2009-05-07
RS52321B (en) 2012-12-31
EA019486B1 (en) 2014-04-30
DOP2010000050A (en) 2010-04-15
ME00979B (en) 2012-06-20
CR11273A (en) 2010-07-16
WO2009056707A3 (en) 2009-10-01
SI2188253T1 (en) 2012-09-28
NI201000023A (en) 2010-03-11
PA8793101A1 (en) 2009-01-23
JP5685440B2 (en) 2015-03-18
JP2010536736A (en) 2010-12-02
NZ583317A (en) 2011-11-25
ECSP109961A (en) 2010-03-31
EP2188253B8 (en) 2012-04-11
PT2188253E (en) 2012-05-11
CN103443076A (en) 2013-12-11
TN2010000025A1 (en) 2011-09-26
CA2696237C (en) 2016-07-05
FR2920023A1 (en) 2009-02-20
HN2010000330A (en) 2012-03-19
WO2009056707A2 (en) 2009-05-07
ATE548349T1 (en) 2012-03-15
KR20100051812A (en) 2010-05-18
DK2188253T3 (en) 2012-07-02
EP2188253B1 (en) 2012-03-07
ZA201001085B (en) 2011-04-28
UA101162C2 (en) 2013-03-11
ES2384080T3 (en) 2012-06-29
MY149649A (en) 2013-09-30
CY1112809T1 (en) 2016-02-10
CO6251363A2 (en) 2011-02-21
EP2188253A2 (en) 2010-05-26
HRP20120466T1 (en) 2012-07-31
MX2010001851A (en) 2010-03-11
AR067937A1 (en) 2009-10-28
GT201000032A (en) 2012-03-12
PL2188253T3 (en) 2012-08-31
UY31297A1 (en) 2009-03-31

Similar Documents

Publication Publication Date Title
EA201070281A1 (en) INDOL-2-ONE DERIVATIVES, DOUBLE SUBSTITUTES IN POSITION 3, THEIR RECEIVING AND THEIR USE IN THERAPY
EA200702347A1 (en) METHOD FOR OBTAINING GLUCOPYRANOSYLESE-SUBSTITUTED DERIVATIVES OF BENZILBENZENE AND INTERMEDIATE PRODUCTS FOR THEIR OBTAINING
EA201790678A1 (en) Bicyclic Heteroaryl Compounds
EA200800760A1 (en) PYRIDOPYRIMIDINONE INHIBITORS PI3Kα
EA201200669A1 (en) PYRIDOPYRIMIDINONE INHIBITORS PI3Kα
EA201000550A1 (en) TIAZOLE DERIVATIVES
EA201070422A1 (en) OXADIAZOL DERIVATIVES
EA200970156A1 (en) PYRDISINOUS DERIVATIVES
EA200701930A1 (en) Derivatives of pyrimidine for the treatment of hyperproliferative disorders
EA201001680A1 (en) COMPOUNDS OF BENZOLSULPHONAMIDTIAOSOL AND OXAZOL
EA201000093A1 (en) PYRIDAZINON DERIVATIVES
EA201070247A1 (en) PROTEAS INHIBITORS
NO20074823L (en) Rasagilin formulations with improved content uniformity
EA201190235A1 (en) SUBSTITUTED 1-CYANOETHYLGETHERO CYCLILCARBOXAMIDE COMPOUNDS 750
EA200801291A1 (en) CARBONYLAMINOPYRROPYRAZOLES AS AN EFFICIENT KINAZ INHIBITORS
EA201100875A1 (en) NEW PYRAZOL-4-N-ALKOXYCARBOXAMIDES AS MICROBIOCIDES
IL204437A (en) Cyclopropyl aryl amide derivatives and uses thereof
EA200901241A1 (en) CONNECTIONS FOR THE TREATMENT OF HEPATITIS C
MX2010003156A (en) Tetrazole-substituted aryl amide derivatives and uses thereof.
EA201170154A1 (en) DERIVATIVES OF PYRIDINOPIRIDINONES, METHOD OF THEIR RECEPTION AND APPLICATION IN THERAPY
EA201070009A1 (en) DERIVATIVES OF 7-ALKINYL-1,8-NAFTYRIDONES, THEIR RECEIVING AND THEIR APPLICATION IN THERAPY
EA200800546A1 (en) BENZIMIDAZOLTHIOPHENE COMPOUNDS AS POLO-SIMILAR KINASE (PLK) INHIBITORS
EA201070804A1 (en) (AZA) INDOL DERIVATIVE, SUBSTITUTED BY SITUATION 5, CONTAINING ITS PHARMACEUTICAL COMPOSITION, INTERMEDIATE COMPOUNDS AND METHOD FOR THEIR PRODUCTION
EA201000895A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIZOSOME DISEASES
EA200801414A1 (en) CALCYLYTIC COMPOUNDS

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU